What decides who gets neuromonitoring in cervical spine surgery?

Advertisement

Income, insurance and hospital type help determine which patients receive intraoperative neuromonitoring during surgery for degenerative cervical myelopathy, according to a study published in the Nov. 15 issue of Spine. Overall use climbed from 23% of cases in 2016 to 34% in 2022.

The analysis dug into 2016 to 2022 National Inpatient Sample data covering 144,769 admissions for adults who underwent cervical decompression, fusion or both for degenerative cervical myelopathy. Cases involving trauma, infection or tumors were excluded. Neuromonitoring was used in 29% of admissions overall.

Patients with private insurance and higher incomes were more likely to be monitored, independent of other factors. The type of surgery mattered too: Fusion procedures, posterior approaches and combined anterior-posterior approaches were all linked to greater use.

So did the hospital. Urban hospitals and private investor-owned hospitals used neuromonitoring more often, and the authors reported a median odds ratio of 3.04, signaling wide differences in use from one hospital to the next.

Geography also played a role. Neuromonitoring was more common in the Pacific, Middle Atlantic, West South Central and Mountain divisions, as defined by the U.S. Census Bureau, and less common in the West North Central and East South Central divisions.

Evidence supporting routine neuromonitoring in cervical spine surgery remains inconclusive, the authors noted, and use may be shaped by institutional and financial factors alongside clinical ones.

Measured clinical, sociodemographic and hospital factors explain only part of the variation, the authors concluded; unmeasured differences in case mix likely contribute, and future research using richer clinical and qualitative data is needed to pinpoint the drivers.

Advertisement

Next Up in Spine

Advertisement